Skip to content

Psychedelic-assisted therapy: all studies

Page 132 of 294: studies 1,311 to 1,320 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

Psilocybin, Lp(a), CAC, Niere und Darmkrebs – Evidenz-Quickies KW 12

EvidenzUpdate March 22, 2026 Denis Nößler

Nach einer Pause gibt es heute wieder Evidenz-Quickies, und zwar gleich mehrere, dafür aber kürzer und weniger ausführlich als zuletzt. Und dieses Format ist jetzt zweigeteilt: (a) Für alle, denen die Nachricht genügt, gibt es oben die Quickies in Kürze. (b) Alle, die weiterlesen wollen, finden die detaillierten Fassungen unten. Viel Freude und hoffentlich interessante Lektüre! 🍄 Psilocybin bei...

DOI: 10.69156/quick/2026.03.00011 (opens in new tab) Primary prevention Vasodilator agents Gynecology

Towards social curative psychedelic treatment

Discover Mental Health March 21, 2026 Martha Newson, Leor Roseman, S. Alexander Haslam

Recent advances in psychedelic-assisted therapies highlight their efficacy in treating various mental health conditions. Nevertheless, the fact that delivery is generally individualised may limit therapeutic outcomes by failing to capitalise on opportunities to build and harness a sense of shared social identity among participants in ways hypothesised by ‘social cure’ research. In line with...

DOI: 10.1007/s44192-026-00426-3 (opens in new tab) Mental health Psychological intervention Identity music Social identity theory +6

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Journal of Psychoactive Drugs March 20, 2026 Marina A. M. Portes, Leandro J Bertoglio

Psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are psychedelic compounds with therapeutic potential for depression, anxiety, and post-traumatic stress. However, their relevance to endurance athletes, who face particular psychological and physical stressors, remains underexplored. This study combines a conceptual overview...

Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy

International Journal of Molecular Sciences March 20, 2026 Ivan Anchesi, Ivana Raffaele, M. Astorino et al.

The clinical renaissance of psychedelic medicine has highlighted the therapeutic potential of rapid-acting neuroplastogens, or "psychoplastogens," for psychiatric disorders. However, the widespread application of classical psychedelics-such as psilocybin and LSD-and the atypical dissociative ibogaine is severely limited by their hallucinogenic properties and, particularly in the case of...

DOI: 10.3390/ijms27062811 (opens in new tab) Neuroplasticity Synaptic plasticity Cognition Schizophrenia object-oriented programming +7

A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies.

European Journal of Psychotraumatology March 19, 2026 Philip Gerrans, Hugh McGovern, Jakob Hohwy et al.

Background: Complex post-traumatic stress disorder (C-PTSD) is a trauma-related condition characterized by pervasive disturbances in affect regulation, self-concept, and interpersonal functioning that extend beyond the symptom profile of post-traumatic stress disorder (PTSD). While neurobiological studies have implicated limbic, salience, and prefrontal systems in C-PTSD, mechanistic accounts...

DOI: 10.1080/20008066.2026.2631358 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine 4-metilendioximetanfetamina C-PTSD MDMA-Assisted Psychotherapy +5

Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies

Discover Mental Health March 19, 2026 Àlvar Farré-colomés, Olga Rublinetska, Oscar Soto-Angona

Psilocybin-assisted therapies are innovative therapeutic approaches, particularly in the treatment of depression. However, there are sparse studies providing functional magnetic resonance imaging (fMRI) evidence elucidating the underlying biological mechanisms that support clinical outcomes. This review aims to comprehensively gather all the evidence reported in psilocybin studies using fMRI...

O potencial terapêutico dos psicodélicos no tratamento de distúrbios neuropsiquiátricos

OUTRAS PALAVRAS March 18, 2026 Gabriela Marques Guimarães Simão, Isabella Andrade Santana, Luiza Paulone Santos Fortunato Dias et al.

O presente estudo aborda o potencial terapêutico dos psicodélicos no tratamento de distúrbios neuropsiquiátricos, destacando sua relevância em um contexto de crescente prevalência de condições como depressão, ansiedade e transtorno de estresse pós-traumático. O objetivo principal é investigar as propriedades farmacológicas desses compostos, seus mecanismos de ação e os resultados clínicos...

DOI: 10.54899/rop.v23n1-2592 (opens in new tab) Anxiety Context archaeology Limiting Work physics +1

Explainable AI framework for psilocybin depression treatment optimization

Frontiers in Computer Science March 16, 2026 Akey Sungheetha, R. Rajesh Sharma, Oluwasegun Julius Aroba et al.

Introduction This computational modeling study introduces a novel Explainable Artificial Intelligence (XAI) framework for optimizing single-dose psilocybin treatment protocols through personalized intervention modeling using publicly available mental health datasets. All results presented are derived from novel simulated data and predictive modeling only, not from real-time clinical...

LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-Being: A Prospective, Naturalistic Study.

Journal of Psychoactive Drugs March 13, 2026 Matthew X. Lowe, Quinn A Darby, Sasha Kalcheff-Korn et al.

Sexual and gender minority (SGM) individuals experience disproportionately high rates of depression, anxiety, trauma, and discrimination, yet remain underrepresented in psychedelic research. This prospective, naturalistic study explored the impact of an ayahuasca retreat experience on mental health, quality of life, and spiritual well-being among SGM participants. Participants attended a...

Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials.

ACS Pharmacology & Translational Science March 13, 2026 Bo Jarrett Wood, M Frances Vest, Catharine Carfagno et al.

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for mood and anxiety disorders, the same conditions under which psychedelic-assisted therapies are gaining renewed interest. However, it remains unclear how SSRI treatment may influence sensitivity to psychedelics, particularly through the shared engagement of serotonergic pathways. Here, we used the head-twitch response...